Prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, has shown potential for cancers that exhibit high DNA replication stress and impaired DNA damage response pathways [37–39], such as HGSOC. The gene discussed is CHEK1; the disease is cancer.